HeartBeam (NASDAQ: BEAT) did not report a revenue figure for Q2 2026 and posted a net loss of $5.0 million, or $0.10 per basic and diluted share, compared with a $5.0 million loss and $0.15 per share a year earlier. Total operating expenses remained near $5.1 million as lower research spending offset higher administrative costs, while quarterly operating cash use declined to $3.3 million.
Core Financial Results
With no revenue figure included in the release, HeartBeam’s quarterly financial picture centered on expenses, losses and cash consumption. The net loss changed little year over year, but the mix of operating expenses shifted substantially.
| Metric | Q2 2026 | Q2 2025 | Year-over-year change |
|---|---|---|---|
| Selling, general and administrative expenses | $2.764 million | $1.711 million | Up approximately 62% |
| Research and development expenses | $2.328 million | $3.326 million | Down approximately 30% |
| Total operating expenses | $5.092 million | $5.037 million | Up approximately 1% |
| Operating loss | $(5.092) million | $(5.037) million | Loss increased approximately 1% |
| Net loss | $(5.039) million | $(4.974) million | Loss increased approximately 1% |
| Basic and diluted EPS | $(0.10) | $(0.15) | Loss per share narrowed by $0.05 |
| Operating cash use | $3.3 million | Approximately $3.4 million | Down 3% |
The improvement in loss per share did not come from higher earnings. HeartBeam’s weighted-average share count increased to 52.8 million from 33.8 million a year earlier, a rise of approximately 56%, spreading a nearly unchanged net loss across more shares.
Commercial and Clinical Progress
HeartBeam advanced the initial commercial launch of its system for arrhythmia assessment. The company reported multiple signed agreements across the New York metropolitan area, Dallas, South Florida and Southern California, while its reader service, onboarding process and customer-support functions were operating. First orders were shipped and initial patients were onboarded during the quarter, but the company did not disclose associated revenue or customer volumes.
The heart attack detection program also moved forward. HeartBeam completed enrollment in the ALIGN-ACS pilot study ahead of schedule, enrolling 134 emergency-department patients at two sites in Serbia. Analysis is underway, with full results scheduled for presentation at TCT 2026 between October 31 and November 3.
In Indonesia, the government-supported HEADSTART-ACS study surpassed 50% enrollment in less than three months. The study is designed to enroll 500 patients and evaluate HeartBeam’s technology for heart attack detection in a real-world setting.
HeartBeam also completed a working prototype of its extended-wear ECG patch and began an approximately 50-patient pilot study. The device combines continuous single-lead monitoring with an on-demand 12-lead ECG mode. It remains under development, and the release did not provide a commercialization or regulatory timeline for the patch.
HeartBeam’s existing FDA clearances cover arrhythmia assessment. The clinical work on heart attack detection is intended to support the design of a future U.S. pivotal study and a subsequent submission seeking an expanded indication.
Flat Net Loss Masked a Major Shift in Spending
SG&A increased by approximately $1.1 million year over year, nearly offsetting the approximately $1.0 million reduction in R&D expenses. The SG&A increase primarily reflected $0.6 million of noncash stock-based compensation related to accelerated equity awards for the former CEO and a $0.3 million severance accrual. Management characterized these costs as one-time items that are not expected to continue beyond June 30, 2026.
The R&D reduction mainly resulted from a $0.7 million decline in product-development and consulting expenses, together with lower headcount-related costs and stock-based compensation. This expense shift kept total operating costs and the net loss close to their prior-year levels despite the substantial changes within individual categories.
Cash Flow and Balance Sheet
Cash and cash equivalents reached $8.7 million on June 30, 2026, up from $4.4 million at the end of 2025. Including restricted cash, the total was $8.8 million.
For the first six months of 2026, operating activities used $7.0 million of cash, compared with $7.9 million in the prior-year period. Financing activities supplied $11.8 million, including $10.3 million of net proceeds from equity sales and $1.5 million through the company’s at-the-market program. The April public offering generated $11.5 million in gross proceeds before underwriting costs and other expenses.
The financing strengthened HeartBeam’s cash position but also increased its share count. Shares outstanding rose to 56.3 million from 40.1 million at the end of 2025, an increase of approximately 40%.
Cash Outflow Guidance
Management lowered its full-year operating cash outflow outlook and expects a further reduction in quarterly cash consumption during Q4. Customer cash receipts could lower Q4 outflow below the stated baseline, although HeartBeam did not quantify those expected receipts.
| Metric | Latest outlook | Previous outlook | Change |
|---|---|---|---|
| Q3 2026 cash outflow | In line with Q2 2026 | Not provided | No direct comparison available |
| Q4 2026 baseline operating cash outflow | Below $2.5 million | Not provided | New quantitative target |
| Full-year 2026 net operating cash outflow | Below $14.0 million | Higher than the latest outlook; exact figure not disclosed | Reduced |
| Cash runway | Further into 2027 | Earlier endpoint not quantified | Extended |
Delivering the expected Q4 step-down will depend on HeartBeam completing its cost-structure changes. Cash collections from commercial contracts represent an additional potential offset but were not included as a quantified amount.
Recent Insider Transactions
Reported insider records show seven purchases on April 16, 2026, totaling approximately $901,000, followed by three stock grants on July 24. The supplied records did not include share quantities for these transactions, and the grants were reported with a transaction value of $0.
| Date | Insider | Position listed | Transaction | Price | Reported value |
|---|---|---|---|---|---|
| July 24, 2026 | Branislav Vajdic | President | Stock grant | $0.00 | $0 |
| July 24, 2026 | Kenneth Harry Persen | Chief Technology Officer | Stock grant | $0.00 | $0 |
| July 24, 2026 | Timothy Cruickshank | Chief Financial Officer | Stock grant | $0.00 | $0 |
| April 16, 2026 | Richard M. Ferrari | Director | Purchase | $0.80 | $50,000 |
| April 16, 2026 | Richard M. Ferrari | Director | Purchase | $0.80 | $46,000 |
| April 16, 2026 | Willem P. Elfrink | Director | Purchase | $0.80 | $150,000 |
| April 16, 2026 | Branislav Vajdic | Director | Purchase | $0.80 | $25,000 |
| April 16, 2026 | Margarita Ortigas-Wedekind | Director | Purchase | $0.80 | $20,000 |
| April 16, 2026 | Mark E. Strome | Director | Purchase, indirect ownership | $0.80 | $600,000 |
| April 16, 2026 | Robert Paul Eno | President | Purchase | $0.80 | $10,000 |
These transactions are presented as reported and do not, by themselves, establish insiders’ expectations for the company’s future performance.
Risks Investors Need to Watch
- Commercial traction remains difficult to quantify. HeartBeam reported agreements, initial shipments and patient onboarding but did not disclose revenue, order volume or contract value.
- Heart attack detection is not part of the current cleared indication. Study results remain pending, and the company has not yet provided detailed timing for a U.S. pivotal study or an FDA submission for indication expansion.
- Cash consumption remains material. Operations used $7.0 million during the first half, while the increase in cash was supported primarily by equity financing.
- Equity financing has increased dilution. Both outstanding shares and the quarterly weighted-average share count rose substantially, affecting the comparability of per-share results.
- The lower cash-burn outlook requires execution. Management expects one-time executive-related expenses to end and baseline Q4 operating cash outflow to fall below $2.5 million, making future expense levels an important measure of progress.
Conclusion
HeartBeam’s Q2 2026 net loss remained near the prior-year level, with lower R&D spending offset by higher SG&A expenses and a larger share count reducing the loss per share. Operationally, the company advanced its initial commercial rollout, completed enrollment in one heart attack study and moved its ECG patch into pilot testing. The next major checkpoints are measurable commercial receipts, pending clinical results, progress toward an expanded FDA indication and delivery of the planned reduction in cash outflow.
Find out more